NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
211 Östergötland |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 651 | 5.2% | 371 | 3.0% | 20 | 0.2% | . | . | 1 | 0.0% | 6 | 0.0% | 11495 | 91.6% | 12544 | 100.0% |
ASCUS | 247 | 16.9% | 466 | 31.9% | 116 | 7.9% | 1 | 0.1% | 1 | 0.1% | 4 | 0.3% | 628 | 42.9% | 1463 | 100.0% |
LSIL | 70 | 8.5% | 302 | 36.6% | 152 | 18.4% | 2 | 0.2% | 3 | 0.4% | 5 | 0.6% | 292 | 35.4% | 826 | 100.0% |
Atypical glandular cells/AGC | 12 | 29.3% | 6 | 14.6% | 1 | 2.4% | 5 | 12.2% | 1 | 2.4% | 1 | 2.4% | 15 | 36.6% | 41 | 100.0% |
Unclear atypia | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% |
ASC-H | 9 | 11.4% | 21 | 26.6% | 46 | 58.2% | 2 | 2.5% | . | . | . | . | 1 | 1.3% | 79 | 100.0% |
HSIL | 6 | 2.3% | 32 | 12.3% | 202 | 77.7% | 5 | 1.9% | 9 | 3.5% | . | . | 6 | 2.3% | 260 | 100.0% |
Suspected Adenocarcinom | 1 | 5.9% | . | . | . | . | 4 | 23.5% | 4 | 23.5% | . | . | 8 | 47.1% | 17 | 100.0% |
Malignant tumor with unclear origin | . | . | . | . | . | . | . | . | 1 | 50.0% | . | . | 1 | 50.0% | 2 | 100.0% |
Squamous cell cancer | . | . | . | . | 2 | 40.0% | . | . | 3 | 60.0% | . | . | . | . | 5 | 100.0% |
Totalt | 996 | 6.5% | 1199 | 7.9% | 539 | 3.5% | 19 | 0.1% | 23 | 0.2% | 16 | 0.1% | 12446 | 81.7% | 15238 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703, M81403, M81409, M83803, M98233 |